1. Home
  2. SPRO vs SWVL Comparison

SPRO vs SWVL Comparison

Compare SPRO & SWVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$0.94

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

SELL

Current Price

$4.82

Market Cap

70.1M

ML Signal

SELL

Company Overview

Basic Information
Metric
SPRO
SWVL
Founded
2013
2017
Country
United States
United Arab Emirates
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
70.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
SPRO
SWVL
Price
$0.94
$4.82
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $5.33
N/A
AVG Volume (30 Days)
★ 320.0K
31.8K
Earning Date
11-12-2026
10-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
N/A
EPS
N/A
★ N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$0.95
$1.30
52 Week High
$3.08
$8.48

Technical Indicators

Market Signals
Indicator
SPRO
SWVL
Relative Strength Index (RSI) 34.32 65.62
Support Level N/A $3.55
Resistance Level $1.27 $8.48
Average True Range (ATR) 0.06 0.40
MACD -0.01 0.10
Stochastic Oscillator 3.18 72.07

Price Performance

Historical Comparison
SPRO
SWVL

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.

Share on Social Networks: